



DOCKET NO.: L00461.70099.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Van den Eynde and Boon-Falleur
Serial No.: 09/674,593
Confirmation No.: 9143
Filing Date: June 7, 2001
Title: TUMOR ASSOCIATED ANTIGEN ENCODED BY THE REVERSE STRAND OF A NEW UBIQUITOUSLY EXPRESSED GENE

Examiner: Misook Yu
Art Unit: 1642

14
100
11-15-22

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 5th day of November, 2002.

June Watson
June Watson

Commissioner for Patents
Washington, DC 20231

RECEIVED
NOV 14 2002
TECH CENTER 1600/2900

Sir:

RESPONSE TO SECOND RESTRICTION REQUIREMENT

In response to the second restriction requirement mailed October 11, 2002, Applicant hereby elects Group II (claims 1-2, 8-9, 12-13, 25, 66-67, and 71-78, as pertaining to SEQ ID NOs:1, 2 and 3) for prosecution, with traverse.

REMARKS

Applicants respectfully traverse the restriction of the RUR-1 sense and RUR-1 antisense sequences, as both groups relate to the same inventive concept of RUR-1 related molecules. The Examiner has asserted that SEQ ID NO:1 and SEQ ID NO:4 are "unrelated sequences." The Examiner appears to base the restriction between the sequences on a conventional definition of "sense" and "antisense" nucleotide sequences. Applicants agree that the claimed RUR-1 "sense" and "antisense" molecules may not fit the conventional definition of such sequences. (Applicants also note that the "antisense" sequences were alternatively termed "RUR-1 antiparallel" and "RUR-1 reverse strand", see first paragraph of Detailed Description). However, the sequences clearly are related, as they appear to be expressed from the same gene as initiated by two different